Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 10.9%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)’s share price dropped 10.9% during trading on Thursday . The stock traded as low as $13.18 and last traded at $13.54. Approximately 1,255,054 shares traded hands during trading, an increase of 62% from the average daily volume of 776,140 shares. The stock had previously closed at $15.19.

Analyst Ratings Changes

DAWN has been the topic of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. JPMorgan Chase & Co. boosted their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, April 22nd. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. Finally, Needham & Company LLC boosted their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Day One Biopharmaceuticals Price Performance

The stock has a 50-day moving average of $15.22 and a two-hundred day moving average of $13.81.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Research analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the sale, the general counsel now directly owns 16,585 shares in the company, valued at approximately $252,921.25. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the transaction, the general counsel now directly owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the transaction, the chief financial officer now directly owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. Insiders sold a total of 55,781 shares of company stock worth $883,160 in the last three months. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Day One Biopharmaceuticals by 8.1% in the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock worth $56,807,000 after purchasing an additional 346,090 shares in the last quarter. Franklin Resources Inc. boosted its stake in Day One Biopharmaceuticals by 4.2% in the fourth quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock worth $61,857,000 after purchasing an additional 169,463 shares in the last quarter. Braidwell LP boosted its stake in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after purchasing an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after purchasing an additional 472,654 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its stake in Day One Biopharmaceuticals by 9.0% in the third quarter. Polar Capital Holdings Plc now owns 1,935,000 shares of the company’s stock worth $23,742,000 after purchasing an additional 160,385 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.